Plain-English translation of NCT06398106 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing a smarter way to use three modern psoriasis medications—secukinumab, ixekizumab, and guselkumab—that work by blocking inflammation in your skin. Instead of giving everyone the same fixed dose, researchers want to see if measuring the actual level of medication in your blood helps doctors personalize your treatment. The goal is to find the dose that works best for you, without giving you too much (which could cause side effects) or too little (which might not clear your skin).
Right now, doctors often prescribe the same dose of these medications to all patients, even though some people absorb or use the medication differently. This can lead to some patients not getting enough benefit, while others get more medication than they need, which increases costs and the risk of side effects. This trial wants to test whether monitoring your blood levels and adjusting your dose based on those results leads to better outcomes.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. One group will continue taking their medication at the standard dose, with dose changes made only if your doctor thinks it's necessary. The other group will have blood tests done every 3 months to measure the level of medication in your body, and your dose will be adjusted based on those results—either by changing how often you take the medication or by increasing or decreasing the amount. Either way, you'll be followed for 18 months with regular visits to check how well your skin is doing and how you're feeling.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
Belgium